secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000950170-23-059042
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel presents preclinical data at SITC for enLIGHTEN platform; Alpha-201-macro1 shows enhanced cancer cell killing
--------------------------------------------------------------------------------

- Preclinical data for enLIGHTEN Discovery Platform presented at SITC 2023 Annual Meeting in San Diego.
- Alpha-201-macro1, first experimental agent from platform, targets CD47/SIRPα pathway via local delivery.
- enLIGHTEN Advanced Analytics suite predicted multi-gene payload combinations from ICI-treated patient datasets.
- Viral chassis Alpha-201 armed with immunostimulatory payloads enhanced PBMC-mediated cancer cell killing in preclinical models.
- Data validate in silico prediction of payload combinations using human datasets to de-risk viral immunotherapy development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023059042/0000950170-23-059042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023059042/cadl-20231104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer